Mar 14, 2017 9:37 am EDT Cerecor Inc. Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
Feb 7, 2017 9:32 am EST Cerecor Engages SunTrust Robinson Humphrey to Assist with Review of Strategic Alternatives
Dec 5, 2016 8:00 am EST Cerecor Announces Top-Line Results from CERC-501 Phase 2 Study for Nicotine Withdrawal
Nov 29, 2016 4:01 pm EST Cerecor Reports Top-Line Data from CERC-301 Phase 2 Study for Major Depressive Disorder
Nov 7, 2016 2:35 pm EST Discovery of Cerecor Drug Candidate CERC-611 (LY3130481) Published in Nature Medicine
Oct 10, 2016 9:10 am EDT Cerecor to Present at the 15th Annual BIO Investor Forum in San Francisco on October 18th, 2016
Sep 26, 2016 9:10 am EDT Cerecor Announces Acquisition of TARP-γ8-AMPA Receptor Antagonist (CERC-611) from Lilly
